Clearside Biomedical Inc

Clearside Biomedical — Technical Presentation (February 2023)

41 slides from Clearside Biomedical's technical presentation, Feb 2, 2023

  1. Slide 1: OASIS Phase 1/2a Clinical Trial 6-Month Extension Study Results

    TM OASIS Phase 1/2a Clinical Trial 6-Month Extension Study Results February 2, 2023 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Developing and Delivering Treatments that Restore and Preserve Vision

    Developing and Delivering Treatments that Restore and Preserve Vision for Serious Back of the Eye Diseases First FDA Approved Product: XIPERE® Proprietary CLS-AX Phase 1/2 data in Wet AMD shows significant reduction in treatment burden and demonstrated a strong duration profile Proprietary Access to

  4. Slide 4: OASIS (3 Month) and Extension Study (6 Month) Cohorts 3 and 4 Summary

    SAFETY DATA Excellent safety profile at all doses and timepoints No Serious Adverse Events No dose limiting toxicities No Adverse Events (AEs) from inflammation No AEs related to intraocular pressure BIOLOGIC EFFECT Stable mean Best Corrected Visual Acuity (BCVA) Stable mean Central Subfield Thickne

  5. Slide 5: CLS-AX (axitinib injectable suspension) for Suprachoroidal Injection

    CLS-AX (axitinib injectable suspension) for Suprachoroidal Injection

  6. Slide 6: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery

    Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery CLS-AX (axitinib injectable suspension) for Suprachoroidal Use May improve the treatment landscape with potential safety, efficacy, durability, and adoption benefits Durable suprachoroidal suspension may reduce patient burden

  7. Slide 7: CLS-AX Injected Suprachoroidally Provides Targeted Delivery

    Plasma CLS-AX at or below level of detection Rabbit Model Values: area under the curve ratios, SCS / IVT SCS : 1 mg/eye, 100 µL. | IVT: 1 mg/eye, 25 µL Single bilateral injection, 1-wk rabbit PK studies High Retina Levels: Sufficient to block VEGF pathway Low Plasma Levels: <1 ng/mL 11x SCS vs IVT R

  8. Slide 8: Trial Design and Objectives

    TRIAL DESIGN AND OBJECTIVES Open-label study with a primary endpoint to evaluate safety and tolerability of escalating single doses of CLS-AX administered through suprachoroidal injection following IVT aflibercept Wet AMD patients with >2 anti-VEGF treatments in the prior 4 months, reading center co

  9. Slide 9: Why target this patient population?

    Why target this patient population instead of treatment naïve or patients with controlled disease? Patients have a high need for effective therapy with lower treatment burden Minimizes the risk of false signals of biologic effect Facilitates assessment for biological effect in a difficult-to-treat n

  10. Slide 10: Wet AMD Disease Characteristics

    Wet AMD Disease Characteristics COHORT 1: 0.03 mg COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg No. of participants 6 5 8 8 Mean age (range), years 81.8 (66-93) 78.2 (65-90) 86.3 (75-97) 76.5 (66-83) Mean baseline best corrected visual acuity (range), letters 59.0 (29-74) 65.6 (52-75) 58.5 (37-

  11. Slide 11: Extension Study: Demographics and Wet AMD History

    Wet AMD Disease Characteristics COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Total No. of participants 2 7 5 14 Mean age (range), years 74.0 (70-78) 87.9 (81-97) 79.6 (74-83) 82.9 (70-97) Mean baseline best corrected visual acuity (range), letters 60.0 (52-68) 59.0 (37-74) 71.2 (69-74) 63.5 (3

  12. Slide 12: OASIS Results: Safety, Durability, & Treatment Burden Reduction

    OASIS Results: Safety, Durability, & Treatment Burden Reduction

  13. Slide 13: CLS-AX Demonstrated a Positive Safety Profile in All Four Cohorts

    3-Month & 6-Month Extension Study Data CLS-AX Demonstrated a Positive Safety Profile in All Four Cohorts Excellent Safety Profile at all doses and timepoints No serious adverse events (SAEs) No treatment emergent adverse events (TEAEs) related to study treatment No dose limiting toxicities No advers

  14. Slide 14: Extension Study (6 Month Data): Prior Anti-VEGF Therapies and All Additional Therapies

    Extension Study (6 Month Data): Prior Anti-VEGF Therapies and All Additional Therapies COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Cohorts 3 & 4 No Additional Therapy ≥ 3 Months: 11/12 (92%) ≥ 4 Months: 10/12 (83%) ≥ 6 Months: 8/12 (67%) > 6 Months: 6/12 (50%) DURABILITY Source: Clearside dat

  15. Slide 15: Extension Study: Additional Therapies Per Protocol Criteria

    Extension Study (6 Month Data): Prior Anti-VEGF Therapies and Additional Therapies Per Protocol Criteria COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg DURABILITY Cohorts 3 & 4 No Additional Therapy ≥ 3 Months: 11/11 (100%) ≥ 4 Months: 10/11 (91%) ≥ 6 Months: 8/11 (73%) > 6 Months: 6/11 (55%) Ex

  16. Slide 16: CLS-AX Demonstrated Reduction of Treatment Burden Across Cohorts

    Extension Study (6 Month): CLS-AX Demonstrated Reduction of Treatment Burden Across Cohorts Observed Reduction in Treatment Burden All Therapies Observed Reduction in Treatment Burden Therapies Per Protocol Criteria Cohort Number of Participants Avg Monthly Injections Before CLS-AX Administration Av

  17. Slide 17: Extension Study (6 Month): Stable Visual Acuity

    Mean Best Corrected Visual Acuity Letter Score, Change from Screening Extension Study (6 Month): Stable Visual Acuity All Data Excluding Data After Additional Treatment Source: Clearside data on file.

  18. Slide 18: Extension Study (6 Month): Stable Central Subfield Thickness

    Mean Central Subfield Thickness, Change from Screening Extension Study (6 Month): Stable Central Subfield Thickness All Data Excluding Data After Additional Treatment Source: Clearside data on file.

  19. Slide 19: 6 Month Case Study: A Biological Effect Following CLS-AX

    Cohort 3, Subject 2: 89 prior anti-VEGF injections with persistent subfoveal fluid 1 month after aflibercept at screen Subretinal fluid gradually resolves through 4 months after CLS-AX with stable BCVA and improved CST 6 Month Case Study: A Biological Effect Following CLS-AX in Anti-VEGF Sub-respond

  20. Slide 20: OASIS Results Potential Competitive Advantages

    OASIS Results Potential Competitive Advantages* Safety Data (All Cohorts) Excellent Safety Profile at all doses and timepoints No SAEs, No TEAEs related to study treatment No dose limiting toxicities No AEs related to inflammation, vasculitis or vascular occlusion No vitreous “floaters” or dispersio

  21. Slide 21: ODYSSEY CLS-AX Phase 2b Clinical Trial

    ODYSSEY CLS-AX Phase 2b Clinical Trial

  22. Slide 22: ODYSSEY Phase 2b Trial in Treatment-Naïve Wet AMD Participants

    Key inclusion criteria: Treatment naïve wet AMD participants Subfoveal CNV secondary to wet AMD Best Corrected Visual Acuity (BCVA) of 78–24 letters* Primary endpoint: Mean change in BCVA Key secondary endpoints: Mean change in Central Subfield Thickness (CST) Treatment burden reduction as measured

  23. Slide 23: Potential to Demonstrate Better Durability and Reduced Treatment Burden

    Potential to Demonstrate Better Durability and Reduced Treatment Burden ODYSSEY Wet AMD Phase 2b Trial – Clinical Rationale Mechanism of Action: Pan-VEGF receptor inhibitor delivered by SCS Microinjector® CLS-AX OASIS Phase 1/2a clinical trial data in treatment-experienced anti-VEGF sub-responders:

  24. Slide 24: ODYSSEY Phase 2b Trial Design

    ODYSSEY Phase 2b Trial Design -8 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 CLS-AX (1.0 mg) Q24W Faricimab-svoa (6.0 mg) Q16W Weeks Baseline Screen Primary Endpoint Secondary Endpoint Blended Timepoint Disease Activity Assessment (DAA) Randomized 1:1 Both Arms: 4 monthly faricimab loading doses; then

  25. Slide 25: ODYSSEY Wet AMD Phase 2b Trial Summary

    ODYSSEY Wet AMD Phase 2b Trial Summary Comparator Treatment-Naïve Participants Maintenance Dosing Regimen Trial Size and Timeline VABYSMO® (faricimab-svoa) is the most recently approved product for wAMD Selected based on KOL input anticipating VABYSMO could become the future branded standard of care

  26. Slide 26: Mark R. Barakat, M.D.

    Director of Retinal Research Institute, Retinal Consultants of Arizona Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine - Phoenix Mark R. Barakat, M.D.

  27. Slide 27: Case Studies

    Gi CLEAR hal BIOMEDICALS NASDAQ: CLSD_

  28. Slide 28: OASIS Case Studies

    OASIS / Ly : Case Studies | ee,

  29. Slide 29: Cohort 3, Subject 3: Durable Stability After CLS-AX

    Cohort 3, Subject 3: 65 prior anti-VEGF injections with PED, mild subfoveal and intraretinal fluid at screen Stable anatomy, BCVA and CST for 6 months after CLS-AX with no additional therapy 6 Month Case Study: Durable Stability After CLS-AX Mild subfoveal fluid Fibrovascular PED Fovea (Macula cente

  30. Slide 30: Cohort 3, Subject 4: Durable Stability After CLS-AX

    6 Month Case Study: Durable Stability After CLS-AX Cohort 3, Subject 4: 14 prior anti-VEGF injections with mild subfoveal fluid at screen Stable anatomy, BCVA and CST for 6 months after CLS-AX with no additional therapy Fovea (Macula Center) Stable, with no progression Mild subfoveal fluid Fibrovasc

  31. Slide 31: Cohort 3, Subject 6: Durable Stability After CLS-AX

    6 Month Case Study: Durable Stability After CLS-AX Screening: Aflibercept BCVA 72, CST 262 Month 3 BCVA 71, CST 207 Baseline: CLS-AX BCVA 71, CST 209 Month 6 BCVA 69, CST 200 Subretinal fluid Fibrovascular PED The cross section is superior to the fovea in the central subfield Cohort 3, Subject 6: 49

  32. Slide 32: Cohort 4, Subject 5: Durable Stability After CLS-AX

    Screening: Aflibercept BCVA 70, CST 244 Month 3 BCVA 69, CST 249 Baseline: CLS-AX BCVA 70, CST 234 Month 6 BCVA 73, CST 246 Intraretinal fluid Shallow fibrovascular PED The cross section is superior to the fovea in the central subfield Cohort 4, Subject 5: 29 prior anti-VEGF injections with persiste

  33. Slide 33: Cohort 4, Subject 6: Durable Stability After CLS-AX

    Cohort 4, Subject 6: 29 prior anti-VEGF injections with PED and mild subfoveal at screen Stable anatomy, BCVA and CST for 6 months after CLS-AX with no additional therapy Fibrovascular PED Fovea (Macula center) Mild subfoveal fluid Source: Clearside data on file. | Previous treatments prior to scree

  34. Slide 34: OASIS Individual Patient Data

    OASIS Individual Patient Data

  35. Slide 35: Anti-VEGF Treatments up to 3 Years Prior to Baseline

    COHORT 3: 0.5 mg COHORT 4: 1.0 mg Source: Clearside data on file. Anti-VEGF Treatments up to 3 Years Prior to Baseline CLS-AX Administration

  36. Slide 36: Extension Study: Reason for Use of Additional Therapies

    Extension Study: Reason for Use of Additional Therapies (in Months 4, 5, 6) COHORT SUBJECT ADDITIONAL THERAPY VISIT REASON FOR ADDITIONAL THERAPY COHORT 2: 0.10 mg (N=2) 1 5 months post CLS-AX Macular hemorrhage COHORT 3: 0.5 mg (N=7) 2 6 months post CLS-AX * BCVA with exudation 5 6 months post CLS-

  37. Slide 37: Cohort 3 Extension Study: Stable BCVA and CST Beyond 3 Months

    Cohort 3 Extension Study: Stable Best Corrected Visual Acuity and Central Subfield Thickness Beyond 3 Months COHORT 3 (0.5 mg): BCVA COHORT 3 (0.5 mg): CST Source: Clearside data on file. Note: Demonstrates data from scheduled and unscheduled visits.

  38. Slide 38: Cohort 4 Extension Study: Stable BCVA and CST Beyond 3 Months

    COHORT 4 (1.0 mg): CST COHORT 4 (1.0 mg): BCVA Dotted line = patient received additional therapy not per protocol (not reading center verified or physician discretion) Cohort 4 Extension Study: Stable Best Corrected Visual Acuity and Central Subfield Thickness Beyond 3 Months Source: Clearside data

  39. Slide 39: Appendix

    OASIS / f, Appendix

  40. Slide 40: ODYSSEY Phase 2b Trial: Control Arm Dosing Per Label

    ODYSSEY Phase 2b Trial: Control Arm Dosing Per Label PRIMARY ENDPOINT 12 16 20 24 28 32 36 40 44 48 52 Weeks -8 -4 0 4 Faricimab 6.0 mg Sham Procedure Disease Activity Assessment Disease Activity Assessment Faricimab-svoa (6.0 mg) Up to Q16W Q12W Q16W* BASELINE SECONDARY ENDPOINT Q8W *Dosing frequen

  41. Slide 41: Clearside Biomedical

    Gi CLEAR hal BIOMEDICALS NASDAQ: CLSD_

Clearside Biomedical — Technical Presentation (February 2023) on 6ix